Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jan. 31, 2024	Mar. 31, 2025
Transaction price
Premium from Third Stock Purchase Agreement Amendment	$ 87
Option continuation payment received in the third quarter of 2024	100
Deferred revenue as of January 2024	335
Total transaction price	522
Allocation to performance obligations
Etrumadenant - License and R&D services	210
Quemliclustat - License and R&D services	168
Domvanalimab - R&D services	33
Access rights	57
Option continuation periods	20
Rights to certain studies	34
Total allocated transaction price	$ 522	$ 35
Inflammation target 1 - R&D services
Allocation to performance obligations
Total allocated transaction price		18
Inflammation target 2 - R&D services
Allocation to performance obligations
Total allocated transaction price		$ 17